We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+11.31%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$826M
AUM Growth
-$75.1M
Cap. Flow
-$116M
Cap. Flow %
-14%
Top 10 Hldgs %
53.79%
Holding
72
New
9
Increased
9
Reduced
17
Closed
17

Top Buys

Rank Stock Value
1
HRTX icon
Heron Therapeutics
HRTX
+$14.5M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.93M
3
ENDP
Endo International plc
ENDP
+$4.02M
4
DXCM icon
DexCom
DXCM
+$3.85M
5
JUNO
Juno Therapeutics, Inc.
JUNO
+$3.77M

Top Sells

Rank Stock Value
1
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$69.4M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$23.5M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$18.6M
4
GNMX
Aevi Genomic Medicine Inc
GNMX
+$15.2M
5
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 77.21%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$83.7M 10.14%
5,664,219
-295,600
-5% -$4.79M
HRTX icon
2
Heron Therapeutics
HRTX
$89.9M
$74.2M 8.99%
4,947,403
+1,047,816
+27% +$14.5M
XBI icon
3
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$69.3M 8.4%
+1,000,000
New +$67.2M
TVTX icon
4
Travere Therapeutics
TVTX
$5.17B
$53.4M 6.47%
2,892,178
-377,093
-12% -$7.38M
AVDL
5
DELISTED
Avadel Pharmaceuticals
AVDL
$42.5M 5.15%
4,394,464
– –
SCTL
6
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$27.1M 3.28%
3,456,596
– –
ANGO icon
7
AngioDynamics
ANGO
$562M
$25.4M 3.08%
1,465,452
-5,700
-0.4% -$95.3K
LJPC
8
DELISTED
La Jolla Pharmaceutical Company
LJPC
$23.4M 2.83%
782,887
-727,429
-48% -$18.6M
RXDX
9
DELISTED
Ignyta, Inc.
RXDX
$22.7M 2.75%
2,637,346
+380,800
+17% +$2.78M
ENDP
10
CALL
DELISTED
Endo International plc
ENDP
$22.3M 2.7%
+2,000,000
New +$24.8M
ATRS
11
DELISTED
Antares Pharma, Inc.
ATRS
$21.7M 2.63%
7,642,206
-5,328,887
-41% -$12.8M
ENDP
12
DELISTED
Endo International plc
ENDP
$21M 2.55%
1,883,738
+323,700
+21% +$4.02M
NVLN
13
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$20.9M 2.53%
1,948,554
– –
PETX
14
DELISTED
Aratana Therapeutics, Inc.
PETX
$19.6M 2.37%
3,695,442
– –
PGNX
15
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$18.9M 2.29%
1,998,531
-6,952,638
-78% -$69.4M
IOVA icon
16
Iovance Biotherapeutics
IOVA
$2.25B
$18.7M 2.26%
2,509,059
-129,200
-5% -$947K
CPRX
17
DELISTED
Catalyst Pharmaceutical
CPRX
$16M 1.94%
8,200,000
– –
VCYT icon
18
Veracyte
VCYT
$4.62B
$15.1M 1.83%
1,648,566
-139,700
-8% -$1.14M
TLGT
19
DELISTED
Teligent, Inc
TLGT
$15.1M 1.83%
193,171
– –
HZNP
20
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$14.8M 1.79%
1,000,000
+200,000
+25% +$3.24M
SBBP
21
DELISTED
Strongbridge Biopharma plc.
SBBP
$14.2M 1.72%
2,981,706
+87,125
+3% +$267K
ADXS
22
DELISTED
Advaxis Inc
ADXS
$12.4M 1.5%
101,284
– –
ELGX
23
DELISTED
Endologix Inc
ELGX
$12.1M 1.46%
166,902
+16,902
+11% +$1.12M
CORI
24
DELISTED
Corium International, Inc.
CORI
$11.7M 1.41%
2,787,121
+867,400
+45% +$3.18M
ARLZ
25
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$11.1M 1.35%
5,191,590
+400,000
+8% +$1.5M
1
2 3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Broadfin Capital held 72 positions worth $826M, down 8.3% from $901M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Broadfin Capital withdrew a net $116M in Q1 2017, closing 17 positions and reducing 17 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $23.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 89% a quarter earlier, followed by Financials.

Against the trend, Broadfin Capital opened a new position in DexCom worth $4.18M.

  • Broadfin Capital's largest Q1 2017 buy was DexCom: 197,200 shares worth $4.18M.
  • Broadfin Capital added most to Heron Therapeutics in Q1 2017, an estimated $14.5M increase.
  • Broadfin Capital's biggest Q1 2017 reduction was Progenics Pharmaceuticals Inc, cutting an estimated $69.4M.
  • Broadfin Capital fully exited Teva Pharmaceuticals in Q1 2017, selling an estimated $23.5M.
  • Broadfin Capital's ten largest holdings make up 54% of its $826M portfolio in Q1 2017.
  • Broadfin Capital opened 9 new positions and closed 17 in Q1 2017.
  • Broadfin Capital's portfolio value fell 8.3% quarter-over-quarter to $826M.

Based on Broadfin Capital's 13F filing for Q1 2017, filed 15 May 2017.